The association between statin use and the diagnosis of prostate cancer in a population based cohort.

The association between statin use and the diagnosis of prostate cancer in a population based cohort.
复制标题

在基于人群的队列中他汀类药物的使用与前列腺癌诊断之间的关联。

DOI:
10.1016/j.juro.2010.03.149
复制
发表时间:
2010-08
期刊:
The Journal of urology
影响因子:
--
通讯作者:
St Sauver JL
St Sauver JL
中科院分区:
其他
文献类型:
--
作者:
Breau RH;Karnes RJ;Jacobson DJ;McGree ME;Jacobsen SJ;Nehra A;Lieber MM;St Sauver JL

文献摘要

参考文献

被引文献

相似文献

使用他汀类药物对前列腺癌风险的影响尚不清楚。我们研究了一个纵向的、基于人群的队列数据,该队列包括2447名年龄在40岁至79岁之间的男性,随访时间为1990年至2007年。关于他汀类药物使用的信息是自我报告的,并通过两年一次的问卷调查获得。随机选择的男性(634; 26%)完成了两年一次的泌尿系统检查,包括血清PSA测量。前列腺活检和前列腺癌的信息通过查阅社区医疗记录获得。在634名他汀类药物使用者中,38名(6%)被诊断患有前列腺癌,而1813名非他汀类药物使用者中有186名(10%)被诊断患有前列腺癌。他汀类药物的使用与接受前列腺活检(HR:0.31; 95% CI:0.24,0.40)、前列腺癌诊断(HR:0.36; 95% CI:0.25,0.53)和高级别(Gleason ≥7)前列腺癌诊断(HR:0.25; 95% CI:0.11,0.58)的风险降低相关。他汀类药物的使用也与超过PSA阈值4.0 ng/mL的风险非显著降低相关(HR:0.63; 95% CI:0.35,1.13)。此外,他汀类药物使用时间较长与这些结局的风险较低相关(所有趋势检验p<0.05)。他汀类药物的使用与前列腺癌诊断风险降低相关。这种关联可以通过检测或癌症预防的减少来解释。
The effect of statin medication use on risk of prostate cancer is unknown. We examined data from a longitudinal, population-based cohort of 2447 men between the ages of 40 and 79 that were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634; 26%) completed biennial urologic examinations that included serum PSA measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. Of 634 statin users, 38 (6%) were diagnosed with prostate cancer compared to 186 (10%) of 1813 non-statin users. Statin use was associated with a decreased risk of receiving a prostate biopsy (HR: 0.31; 95% CI: 0.24, 0.40), prostate cancer diagnosis (HR: 0.36; 95% CI: 0.25, 0.53) and high-grade (Gleason ≥7) prostate cancer diagnosis (HR: 0.25; 95% CI: 0.11, 0.58). Statin use was also associated with a non-significant decreased risk of exceeding a PSA threshold of 4.0 ng/mL (HR: 0.63; 95% CI: 0.35, 1.13). In addition, longer duration of statin use was associated with lower risk of these outcomes (all tests for trend p<0.05). Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention.
DOI: 10.3322/caac.20006
发表时间: 2009-07-01
影响因子: 254.7
作者:
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者: Thun, Michael J.
DOI: 10.1093/jnci/djj499
发表时间: 2006-12-20
影响因子: 10.3
作者:
Platz, Elizabeth A.;Leitzmann, Michael F.;Giovannucci, Edward
通讯作者: Giovannucci, Edward
DOI: 10.1001/archinte.160.15.2363
发表时间: 2000-08-14
影响因子: --
作者:
Blais, L;Desgagné, A;LeLorier, J
通讯作者: LeLorier, J
DOI: 10.1001/jama.287.24.3215
发表时间: 2002-06-26
影响因子: 120.7
作者:
Serruys, PWJC;de Feyter, P;Meier, B
通讯作者: Meier, B
全科医学研究数据库中他汀类药物的使用和癌症风险。
DOI: 10.1038/sj.bjc.6601566
发表时间: 2004-02-09
影响因子: 8.8
作者:
Kaye, JA;Jick, H
通讯作者: Jick, H